Skip to main content

Table 2 Input parameters in the partitioned survival model

From: Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach

 

Baseline value ($)

Range ($)

Distribution

Reference

Durvalumab

7,866.6/ 1,500 mg

5,899.95–9,833.25

lognormal

[20]

Atezolizumab

4,755/1,200 mg

3,566.25–5,943.75

lognormal

[20]

Pembrolizumab

2,612.83/100 mg

1,959.69–3,266.11

lognormal

[27]

Nivolumab

665/40 mg

498.75–831.25

lognormal

[20]

Ipilimumab

81.2/mg

60.9–101.5

lognormal

[20]

Sintilimab

157.5/100 mg

118.13–196.88

lognormal

[28]

Camrelizumab

426.9/200 mg

320.2–533.7

lognormal

[29, 30]

Tislelizumab

317.89/100 mg

238.42–397.36

lognormal

[31]

Bevacizumab

262.5/100 mg

196.88–328.13

lognormal

[32]

Tremelimumaba

81.2/mg

60.9–101.5

lognormal

-

Carboplatin

0.16/mg

0.12–0.21

lognormal

[27]

Pemetrexed

131.24/100 mg

98.43–164.05

lognormal

[32]

Docetaxel

189.57/200 mg

142.18–236.96

lognormal

[33]

Cost of medical service of immunotherapy per cycle

8.20

6.15–10.25

lognormal

[27]

Cost of medical service of chemotherapy per cycle

45.97

34.48–57.47

lognormal

[27]

Follow-up cost per cycle

58.53

43.90–73.17

lognormal

[27, 34]

Utility for PFS

0.804

0.683–0.925

beta

[35]

Utility for PD

0.321

0.273–0.369

beta

[35]

Utility for death

0

0

-

-

Discount rate

5%

0–8%

-

[25]

  1. aThe price of tremelimumab was assumed to be identical to that of ipilimumab, because tremelimumab was not approved to enter into the market